Single-batch production of recombinant human polyclonal antibodies

Molecular Biotechnology

Volumn 45, Issue 3, 2010, Pages 257-266

  Nielsen, Lars S ^a   Baer, Alexandra ^a   Müller, Christian ^a   Gregersen, Kristian ^a   Mønster, Nina T ^a   Rasmussen, Søren K ^a   Weilguny, Dietmar ^a   Tolstrup, Anne B ^a  

^a Symphogen AS   (Denmark)

Author keywords

Antibody production; Batch to batch consistency; CHO DG44; Clonal cell lines; Compositions of cell lines; DHFR selection; Random integration; Recombinant polyclonal antibodies; Single batch manufacturing

Indexed keywords

CELL CULTURE; CLONE CELLS; INTEGRATION; MANUFACTURE; RECOMBINANT PROTEINS;

ANTIBODY PRODUCTION; BATCH MANUFACTURING; BATCH-TO-BATCH CONSISTENCY; CELL LINES; CHO-DG44; DHFR SELECTION; POLYCLONAL ANTIBODY;

ANTIBODIES;

POLYCLONAL ANTIBODY; RECOMBINANT ANTIBODY;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; GENE EXPRESSION; GENETIC ENGINEERING; HUMAN; NONHUMAN; PROTEIN TARGETING; REPRODUCIBILITY;

EID: 77954959328     PISSN: 10736085     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12033-010-9270-9     Document Type: Article

References (16)

1. Casadevall, A., & Scharff, M. D. (1995). Return to the past: The case for antibody-based therapies in infectious diseases. Clinical Infectious Disease, 21, 150-161.
2. Hadley, A. G., Poole, G. D., Poole, J., Anderson, N. A., & Robson, M. (1996). Haemolytic disease of the newborn due to anti-G. Vox Sanguinis, 71, 108-112.
3. Scaradavou, A., Woo, B., Woloski, B. M. R., Cunningham- Rundles, C., Ettinger, L. J., Aledort, L. M., et al. (1997). Intravenous anti-D treatment of immune thrombocytopenic purpura: Experience in 272 patients. Blood, 89, 2689-2700.
4. Casadevall, A., Dadachova, E., & Pirofski, L. A. (2004). Passive antibody therapy for infectious diseases. Nature Reviews. Microbiology, 2, 695-703.
5. Sharon, T., Liebman, M. A., & Williams, B. R. (2005). Recombinant polyclonal antibodies for cancer therapy. Journal of Cellular Biochemistry, 96, 305-313.
6. Rasmussen, S. K., Rasmussen, L. K., Weilguny, D., & Tolstrup, A. B. (2007). Manufacture of recombinant polyclonal antibodies. Biotechnology Letters, 29, 845-852.
7. Haurum, J. S., & Bregenholt, S. (2005). Recombinant polyclonal antibodies: Therapeutic antibody technologies come full circle. IDrugs, 8, 404-409.
8. Cane, P. A. (2001). Molecular epidemiology of respiratory syncytial virus. Reviews in Medical Virology, 11, 103-116.
9. Chadd, H. E., & Chamow, S. M. (2001). Therapeutic antibody expression technology. Current Opinion in Biotechnology, 12, 188-194.
10. Kipriyanov, S. M., & Le Gall, F. (2004). Generation and production of engineered antibodies. Molecular Biotechnology, 26, 39-60.
11. Wurm, F. M. (2004). Production of recombinant protein therapeutics in cultivated mammalian cells. Nature Biotechnology, 22, 1393-1398.
12. O'Gorman, S., Fox, D. T., & Wahl, G. M. (1991). Recombinasemediated gene activation and site-specific integration in mammalian cells. Science, 251, 1351-1355.
13. Wiberg, F. C., Rasmussen, S. K., Frandsen, T. P., Rasmussen, L. K., Tengbjerg, K., Coljee, V. W., et al. (2006). Production of target-specific recombinant human polyclonal antibodies in mammalian cells. Biotechnology and Bioengineering, 94, 396-405.
14. Meijer, P. J., Andersen, P. S., Haahr, H. M., Steinaa, L., Jensen, A., Lantto, J., et al. (2006). Isolation of human antibody repertoires with preservation of the natural heavy and light chain pairing. Journal of Molecular Biology, 358, 764-772.
15. Jones, D., Kroos, N., Anema, R., Van Montfort, B., Vooys, A., Van Der, K. S., et al. (2003). High-level expression of recombinant IgG in the human cell line per.c6. Biotechnology Progress, 19, 163-168.
16. Mazur, X., Fussenegger, M., Renner, W. A., & Bailey, J. E. (1998). Higher productivity of growth-arrested Chinese hamster ovary cells expressing the cyclin-dependent kinase inhibitor p27. Biotechnology Progress, 14, 705-713.